Private biotech M&A surges amid difficult IPO market

[cafead]

via At the start of 2024, optimism had returned to biotech. Investor cash flowed back toward drug companies and initial public offerings, a useful barometer of the sector’s health, picked up in a sign of the market’s strengthening.

article source